Goldman Sachs Group Inc Larimar Therapeutics, Inc. Transaction History
Goldman Sachs Group Inc
- $596 Billion
- Q1 2025
A detailed history of Goldman Sachs Group Inc transactions in Larimar Therapeutics, Inc. stock. As of the latest transaction made, Goldman Sachs Group Inc holds 2,671,271 shares of LRMR stock, worth $10.7 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
2,671,271
Previous 2,671,271
-0.0%
Holding current value
$10.7 Million
Previous $5.74 Million
-0.0%
% of portfolio
0.0%
Previous 0.0%
Shares
18 transactions
Others Institutions Holding LRMR
# of Institutions
119Shares Held
65MCall Options Held
93.5KPut Options Held
68K-
Deerfield Management Company, L.P. (Series C) New York, NY21.2MShares$84.9 Million1.16% of portfolio
-
Ra Capital Management, L.P. Boston, MA6.05MShares$24.2 Million0.27% of portfolio
-
Janus Henderson Group PLC London, X05.57MShares$22.3 Million0.01% of portfolio
-
Blue Owl Capital Holdings LP New York, NY4.78MShares$19.1 Million5.31% of portfolio
-
Chi Advisors LLC New York, NY3.41MShares$13.7 Million6.65% of portfolio
About Larimar Therapeutics, Inc.
- Ticker LRMR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 43,269,200
- Market Cap $173M
- Description
- Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease. T...